Company / R&D per Share
Supernus Pharmaceuticals, Inc. R&D per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D per Share
$1.91
FY2025
5-year range
$1.40 / $1.99
FY2021-FY2025
Trend
-4.1%
vs FY2024
Sector context
#106 of 208
Health Care
What the data says
At $1.91, Supernus Pharmaceuticals, Inc.'s r&d per share ranks #106 of 208 in the Health Care sector. R&D per Share has fluctuated over the past 10 years, ranging from $0.40 in FY2016 to $1.99 in FY2024.
Based on SEC 10-K filings.
1.91 in FY2025 with a 5-year CAGR of +5.7%.
Improved from $1.65 to $1.91 over the past 2 years.
Health Care sector context is included.
R&D per Share over time
Growth rates
- 3-Year CAGR
- +10.8%
- 5-Year CAGR
- +5.7%
- 10-Year CAGR
- -
Sector benchmark
#106 of 208 in Health CareTop 51% of 208This company $1.91 Sector average $28.82
▼
-93.4% below sector average
Key checks
Key Insights
- In FY2025, r&d per share decreased 4.1% year-over-year.
- Ranks #106 out of 208 companies in the Health Care sector.
- Peak r&d per share was recorded in FY2024.
- Lowest r&d per share in the period was in FY2016.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $1.91 | -4.1% |
| FY2024 | $1.99 | +20.5% |
| FY2023 | $1.65 | +17.9% |
| FY2022 | $1.40 | -18.2% |
| FY2021 | $1.71 | +18.3% |
| FY2020 | $1.45 | +9.5% |
| FY2019 | $1.32 | +58.4% |
| FY2018 | $0.83 | +43.0% |
| FY2017 | $0.58 | +45.9% |
| FY2016 | $0.40 | -41.0% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026